What Is PT-141? Mechanism, Uses, Risks, and FDA Status
What Is PT-141?
PT-141, also known by its generic name bremelanotide, is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. Unlike PDE5 inhibitors (such as sildenafil) that work on vascular mechanisms, PT-141 acts directly on the central nervous system to modulate sexual desire and arousal. It was originally derived from the tanning peptide Melanotan II during research that unexpectedly revealed potent pro-sexual effects. In 2019, the FDA approved bremelanotide (marketed as Vyleesi) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
How Does PT-141 Work?
PT-141 activates melanocortin receptors, primarily MC3R and MC4R, in the hypothalamus and limbic system — brain regions involved in sexual motivation and arousal. This mechanism is fundamentally different from vascular-based treatments:
- Central nervous system action — Rather than increasing blood flow to genitalia, PT-141 modulates neural pathways governing desire and arousal
- MC4R activation — Research suggests MC4R signaling in the paraventricular nucleus is critical for the pro-sexual effects (Pfaus et al., Neuroscience & Biobehavioral Reviews, 2004)
- Dopaminergic involvement — Downstream effects include modulation of dopamine release in reward circuits, which may explain the subjective increase in desire
- Gender-independent mechanism — Unlike many sexual dysfunction treatments, the central mechanism appears effective across biological sexes in preclinical models
The peptide is administered subcutaneously and reaches peak plasma concentration within approximately 1 hour, with effects lasting 12–24 hours in clinical studies.
What Is PT-141 Used For?
Based on published research and its FDA-approved indication:
- Hypoactive sexual desire disorder (HSDD) in women — FDA-approved indication (Vyleesi); Phase III trials demonstrated statistically significant increases in desire and reductions in distress (Kingsberg et al., Obstet Gynecol, 2019)
- Erectile dysfunction in men — Phase II trials showed efficacy in men who did not respond to PDE5 inhibitors (Diamond et al., Int J Impot Res, 2004)
- Situational sexual dysfunction — Research into on-demand use for both sexes
- Melanocortin system research — Used as a tool compound to study MC3R/MC4R signaling in appetite, energy homeostasis, and social behavior
What Are the Risks and Side Effects?
- Nausea — The most common side effect, reported in approximately 40% of women in clinical trials; typically mild to moderate and transient
- Flushing — Facial flushing occurs in roughly 20% of users
- Headache — Reported in approximately 11% of clinical trial participants
- Injection site reactions — Bruising, redness, and discomfort at the subcutaneous injection site
- Transient blood pressure elevation — Small, temporary increases in systolic and diastolic blood pressure have been observed; PT-141 is contraindicated in uncontrolled hypertension
- Hyperpigmentation — Darkening of skin (particularly facial) has been reported with repeated use, related to melanocortin activation
- Dosing limitations — The FDA label recommends no more than one dose per 24 hours and no more than 8 doses per month
- Cardiovascular caution — Not recommended for patients with cardiovascular disease due to transient hemodynamic effects
FDA Status
PT-141 (bremelanotide) is FDA-approved under the brand name Vyleesi for the treatment of acquired, generalized HSDD in premenopausal women. It was approved in June 2019. For men with erectile dysfunction, it remains investigational — Phase II trials were completed but no NDA has been filed for this indication. The compound is also available through compounding pharmacies for off-label use under physician supervision. For the latest regulatory updates, visit our FDA tracker.
Key Studies and Evidence Base
| Study | Finding | |-------|---------| | Kingsberg et al., 2019 (Obstet Gynecol) | Phase III: Significant increase in sexual desire and decrease in distress vs. placebo in premenopausal women with HSDD | | Diamond et al., 2004 (Int J Impot Res) | Phase II: 68% of men with ED achieved erections sufficient for intercourse, including PDE5i non-responders | | Clayton et al., 2016 (J Sex Med) | RECONNECT trials: Consistent efficacy across two Phase III studies with 1,247 women | | Pfaus et al., 2004 | Mechanistic evidence for MC4R-mediated pro-sexual effects in CNS |
The Bottom Line
PT-141 represents a unique approach to sexual dysfunction by targeting central nervous system pathways rather than peripheral vascular mechanisms. With FDA approval for HSDD in women and promising Phase II data in men, it has the strongest regulatory standing of any peptide-based sexual health treatment. The most significant limitation is the high incidence of nausea, which affects tolerability for some patients. It should be used under medical supervision, particularly in individuals with cardiovascular risk factors.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. TruPeptide does not sell peptides or facilitate purchases.